Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
- None.
- None.
Insights
The filing of a registration statement on Form S-1 by Invizyne Technologies for a firm commitment public offering is a significant event for the company and its parent, MDB Capital Holdings. The offering size of 4.3 million shares at $4.00 each indicates a capital raise of $17.2 million, which is a substantial influx of funds that could be used to fuel the company's growth, R&D efforts, or expansion of operations. The pricing of the shares and the total amount to be raised are crucial for investors to evaluate the company's valuation and the dilution effect on current shareholders.
The preference given to holders of MDB Class A Shares in the allocation of the offering suggests a strategic move to reward and possibly retain loyal investors, which may influence investor sentiment and stock performance. Additionally, the involvement of Public Ventures, LLC as the underwriter, given its affiliation with MDB, raises questions about the objectivity of the offering process, which investors need to consider.
Lastly, the company's intention to list on The Nasdaq Stock Market under the ticker 'IZTC' is an important step towards increasing visibility and liquidity for the company's shares. However, the success of the offering and subsequent stock performance will be contingent on investor perception of the company's potential and the broader market conditions at the time of the offering.
The biomanufacturing industry is becoming increasingly competitive, with a strong emphasis on innovation and cost-efficiency. Invizyne Technologies' focus on enzyme-based biomanufacturing systems places it in a niche market with significant growth potential. The funds raised from the public offering could be instrumental in advancing the company's technology and securing a competitive position in the market.
Investors should consider the growth trajectory of the biomanufacturing sector and Invizyne's potential market share. The company's ability to capitalize on the proceeds from the offering to drive technological advancements and commercialize its products will be critical for its long-term success. Additionally, the alignment of Invizyne's product offerings with current market trends and demands will be a key determinant of the company's performance post-IPO.
The announcement mentions that the registration statement has been filed with the SEC but is not yet effective. This is a standard regulatory step in the process of a public offering and it means that the securities cannot be sold nor can offers to buy be accepted until the registration statement is declared effective by the SEC. It is important for potential investors to understand that the prospectus included in the registration statement will provide detailed information about the offering, the company's financials, risks and management's discussion and analysis, which is essential for making an informed investment decision.
Additionally, the relationship between Public Ventures, LLC, MDB and Invizyne raises potential conflict of interest concerns that the SEC may scrutinize during the review process. It is incumbent upon the underwriters to ensure that the offering is conducted in compliance with securities laws and that all potential conflicts are adequately disclosed to investors.
Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") – today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering.
The offering shall be for 4,300,000 shares of common stock at a price per share of
Public Ventures, LLC will be acting as the underwriter and sole book manager for the proposed offering. Digital Offering, LLC will be acting as the qualified independent underwriter. Public Ventures, LLC is a subsidiary of MDB and an affiliate of Invizyne.
In allocating the shares to be sold, Public Ventures, LLC intends to give preference to holders of MDB Class A Shares, after which it will give preference to the other beneficial shareholders of MDB and then of Invizyne. To the extent these foregoing groups do not purchase all the available shares, including the overallotment, then shares will be sold to other persons making an indication for purchase of shares through their respective brokers or dealers.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A copy of the prospectus related to the offering and included in the registration statement, when available, may be obtained by visiting the SEC website or by emailing Invizyne’s Investor Relations department at IR@invizyne.com.
About Invizyne Technologies, Inc.
Invizyne Technologies, Inc., a subsidiary of MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") (www.mdb.com), is an enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after chemicals. The management of Invizyne believes that the Invizyne biomanufacturing platform, known as SimplePath™, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for SimplePath™ platform is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. The SimplePath™ platform not only can maximize the value of these resources but also will contribute to the development of novel chemical compounds that should open new markets and business opportunities.
For more information, please visit www.invizyne.com
Media contacts: press@invizyne.com
Partnership contacts: partners@invizyne.com
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
FAQ
What is the ticker symbol for Invizyne Technologies after the offering?
How many shares of common stock are being offered by Invizyne Technologies?
What is the price per share for the common stock in the offering?
Who is acting as the underwriter and sole book manager for the proposed offering?
How can one obtain a copy of the prospectus related to the offering?
